Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Hospira 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Hospira 2Q11

Docetaxel fuels revenue growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Hospira 2Q

2Q Revenues: $1.1 billion (+10%)

2Q Earnings: $144 million (+72%)

YTD Revenues: $2.1 billion (+5%)

YTD Earnings: $294 million (+30%)

Comments: Revenue growth in 2Q11 was driven primarily by sales of oncolytic docetaxel in the Specialty Injectables group. Sales for that unit were $675 million (+18%) in 2Q and $1.3 billion YTD (+11%). Sales for Other Pharma, which includes contract manufacturing, were down 5% for 2Q ($142 million) and down 10% YTD ($266 million).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics